[1] HAMIEH M, DOBRIN A, CABRIOLU A, et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape[J]. Nature, 2019, 568(7750):112-116. [2] 张之南, 沈悌. 血液病诊断及疗效标准[M]. 3版. 北京:科学出版社, 2007:233. [3] 陈辉树, 刘恩彬, 王婷婷, 等. 131例浆细胞性骨髓瘤的病理形态与临床研究[J]. 中华病理学杂志, 2004, 33(1):44-48. [4] 刘爱宁, 陈辉树, 刘恩彬, 等. 161例慢性特发性骨髓纤维化临床病理分期的探讨[J]. 中华血液学杂志, 2006, 27(3):178-182. [5] YU L, CHEN K, XU Y, et al. The value of EUS in combination with cytological, flow cytometry, and gene rearrangement in the diagnosis of gastrointestinal lymphoma[J]. Hematol Oncol, 2017, 35(3):303-309. [6] MC CORMICK KA, CHEN X, WALTER RB, et al. Mott-cells[J]. Eur J Haematol, 2013, 90(1):83. [7] MATSUE K, MATSUE Y, KUMATA K, et al. Quantification of bone marrow plasma cell infiltration in multiple myeloma:usefulness of bone marrow aspirate clot with CD138 immunohistochemistry[J]. Hematol Oncol, 2017, 35(3):323-328. [8] VELA-OJEDA J, ESPARZA M A G R, MAJLUF-CRUZ A, et al. Post-treatment improvement of NK cell numbers predicts better survival in myeloma patients treated with thalidomide-based regimens[J]. Int J Hematol, 2019, 110(3):306-312. [9] CHEN C C, YANG C F, YANG M H, et al. Pretreatment prognostic factors and treatment outcome in elderly patients with denovo acute myeloid leukemia[J]. Ann Oncol, 2005, 16(8):1366-1373. [10] 唐巧云, 谢燕, 王翎, 等. 老年多发性骨髓瘤肾损害103例的临床特点[J]. 中国老年学杂志, 2011, 31(2):189-192. [11] GAVILE C M, BARWICK B G, NEWMAN S, et al. CD86 regulates myeloma cell survival[J]. Blood Adv, 2017, 1(25):2307-2319. [12] GOGIA A, SIKKA M, SHARMA S, et al. Hemostatic abnormalities in multiple myeloma patients[J]. Asian Pac J Cancer Prev, 2018, 19(1):127-130. [13] UNDAS A, ZUBKIEWICZ-USNARSKA L, HELBIG G, et al. Induction therapy alters plasma fibrin clot properties in multiple myeloma patients:association with thromboembolic complications[J]. Blood Coagul Fibrinolysis, 2015, 26(6):621-627. [14] MCGREGOR S, MCNEER J, GURBUXANI S. Beyond the 2008 World Health Organization classification:the role of the hematopathology laboratory in the diagnosis and management of acute lymphoblastic leukemia[J]. Semin Diagn Pathol, 2012, 29(1):2-11. [15] 王慧, 刘露, 刘芳, 等. CD27抗原在多发性骨髓瘤诊断中的价值[J]. 中国实验血液学杂志, 2017, 25(4):1069-1073. [16] YANG Q, CAO W, WANG Z, et al. Regulation of cancer immune escape:The roles of miRNAs in immune checkpoint proteins[J]. Cancer Lett, 2018, 431:73-84. [17] MÁRK Á, VARGA G, TIMÁR B, et al. The effect of microenvironmental factors on the development of myeloma cells[J]. Hematol Oncol, 2017, 35(4):741-745. [18] 葛芳芳, 田文亮, 孙慧敏, 等. CD28和CD117在初诊多发性骨髓瘤患者中的表达及其临床意义[J]. 白血病·淋巴瘤, 2019, 28(5):263-267. [19] SKERGET M, SKOPEC B, ZADNIK V, et al. CD56 expression is an important prognostic factor in multiple myeloma even with bortezomib induction[J]. Acta Haematol, 2018, 139(4):228-234. |